$GALT
GALECTIN THERAPEUTICS INC Stock $galt

$galt Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000119312518100592 Filed on March 29, 2018

Income Statement

Concept	2018 Q1	2016 Q4	2016
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.880M	$1.170M	$6.160M
YoY Change	60.68%	-33.9%	-11.62%
% of Gross Profit
Research & Development	$2.298M	$3.430M	$15.33M
YoY Change	-39.08%	17.87%	16.86%
% of Gross Profit
Depreciation & Amortization	$0.00	$0.00	$7.000K
YoY Change	-100.0%		0.0%
% of Gross Profit
Operating Expenses	$4.178M	$4.600M	$21.48M
YoY Change	-15.53%	-1.71%	6.98%
Operating Profit	-$4.178M		-$21.48M
YoY Change	-15.53%		6.98%
Interest Expense	$84.00K	$10.00K	$50.00K
YoY Change	740.0%	0.0%	0.0%
% of Operating Profit
Other Income/Expense, Net	-$80.00K		$45.00K
YoY Change	-988.89%		-13.46%
Pretax Income	-$4.260M	-$4.590M	-$21.44M
YoY Change	-13.77%	-1.71%	7.04%
Income Tax
% Of Pretax Income
Net Earnings	-$4.258M	-$4.590M	-$21.44M
YoY Change	-13.75%	-1.73%	7.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$114.3K	-$154.4K	-$733.7K
COMMON SHARES
Basic Shares Outstanding	37.57M shares	29.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2016 Q4	2016
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.990M	$15.36M	$15.36M
YoY Change	-70.75%	-40.58%	-40.58%
Cash & Equivalents	$3.988M	$15.36M	$15.36M
Short-Term Investments
Other Short-Term Assets	$690.0K	$430.0K	$430.0K
YoY Change	97.14%	-21.82%	-21.82%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$4.673M	$15.79M	$15.79M
YoY Change	-66.61%	-40.17%	-40.19%
LONG-TERM ASSETS
Property, Plant & Equipment		$0.00	$0.00
YoY Change
Goodwill
YoY Change
Intangibles		$1.000K
YoY Change		-87.5%
Long-Term Investments
YoY Change
Other Assets	$258.0K
YoY Change
Total Long-Term Assets	$258.0K	$1.000K	$10.00K
YoY Change		-87.5%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$4.673M	$15.79M	$15.79M
Total Long-Term Assets	$258.0K	$1.000K	$10.00K
Total Assets	$4.931M	$15.80M	$15.80M
YoY Change	-64.77%	-40.19%	-40.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.151M	$910.0K	$910.0K
YoY Change	-14.49%	103.13%	102.22%
Accrued Expenses	$1.132M	$2.802M	$2.800M
YoY Change	-62.47%	231.6%	229.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.283M	$3.780M	$3.780M
YoY Change	-47.66%	177.94%	177.94%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.283M	$3.780M	$3.780M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.283M	$3.780M	$3.780M
YoY Change	-47.66%	177.94%	177.94%
SHAREHOLDERS EQUITY
Retained Earnings	-$185.7M	-$163.7M
YoY Change	9.95%	16.89%
Common Stock	$38.00K	$33.00K
YoY Change	8.57%	17.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$925.0K	$10.29M	$12.02M
YoY Change
Total Liabilities & Shareholders Equity	$4.931M	$15.80M	$15.80M
YoY Change	-64.77%	-40.19%	-40.17%

Cashflow Statement

Concept	2018 Q1	2016 Q4	2016
OPERATING ACTIVITIES
Net Income	-$4.258M	-$4.590M	-$21.44M
YoY Change	-13.75%	-1.73%	7.04%
Depreciation, Depletion And Amortization	$0.00	$0.00	$7.000K
YoY Change	-100.0%		0.0%
Cash From Operating Activities	-$3.516M	-$4.870M	-$16.41M
YoY Change	-8.91%	5.87%	-3.36%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$4.451M		$5.925M
YoY Change	107.51%		-56.75%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.451M	4.170M	5.930M
YoY Change	107.02%	-54.33%	-56.72%
NET CHANGE
Cash From Operating Activities	-3.516M	-4.870M	-16.41M
Cash From Investing Activities		0.000	0.000
Cash From Financing Activities	4.451M	4.170M	5.930M
Net Change In Cash	935.0K	-700.0K	-10.48M
YoY Change	-154.68%	-115.45%	219.51%
FREE CASH FLOW
Cash From Operating Activities	-$3.516M	-$4.870M	-$16.41M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		-$4.870M	-$16.41M
YoY Change		5.87%	-3.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2008Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.00
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25846000
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32912942	shares
CY2016Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1272650	shares
CY2008Q1	us-gaap	Share Price SharePrice	3.54
CY2008Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	984000
CY2008Q1	galt	Class Of Warrant Or Right Issued ClassOfWarrantOrRightIssued	1400	shares
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	37569866	shares
CY2017Q2	dei	Entity Public Float EntityPublicFloat	67000000
CY2010Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.20
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3342325	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.70
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	18040000
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32912942	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4656888	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.30
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163701000
CY2016Q4	us-gaap	Liabilities Liabilities	3780000
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15795000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	614000
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	910000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	10292000
CY2016Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	68000
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	33000
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	166721000
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74000
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	14000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	77000
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3780000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	51121000
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2802000
CY2016Q4	us-gaap	Assets Current AssetsCurrent	15794000
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5707000
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2016Q4	us-gaap	Security Deposit SecurityDeposit	6000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15362000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44219000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1195000
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1000
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74000
CY2016Q4	us-gaap	Assets Assets	15795000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	51121000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	78000
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	432000
CY2016Q4	galt	Undesignated Capital Stock Shares Authorized UndesignatedCapitalStockSharesAuthorized	20000000	shares
CY2016Q4	galt	Undesignated Capital Stock Shares Outstanding UndesignatedCapitalStockSharesOutstanding	14001000	shares
CY2016Q4	galt	Undesignated Capital Stock Par Value UndesignatedCapitalStockParValue	0.01
CY2016Q4	galt	Undesignated Capital Stock Value UndesignatedCapitalStockValue	0
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35789388	shares
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	4526679	shares
CY2017Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	5155263	shares
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	4.11
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	628584	shares
CY2017Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	500000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35789388	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4526679	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.37
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5155263	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.11
CY2017Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	4.37
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13229778	shares
CY2017Q4	us-gaap	Share Price SharePrice	3.34
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-181168000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	48000
CY2017Q4	us-gaap	Liabilities Liabilities	2968000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4161000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	790000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	608000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-530000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	48000
CY2017Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	68000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	36000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	173363000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	74000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	74000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	78000
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39432000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2968000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	39432000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2292000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	3819000
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4064000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	0
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	6000
CY2017Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4175000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3053000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	34173000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	1195000
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	1036000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	74000
CY2017Q4	us-gaap	Assets Assets	4161000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	78000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	342000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	766000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4824000
CY2017Q4	galt	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
CY2017Q4	galt	Undesignated Capital Stock Shares Authorized UndesignatedCapitalStockSharesAuthorized	20000000	shares
CY2017Q4	galt	Undesignated Capital Stock Shares Outstanding UndesignatedCapitalStockSharesOutstanding	20000000	shares
CY2017Q4	galt	Undesignated Capital Stock Shares Authorized But Unissued UndesignatedCapitalStockSharesAuthorizedButUnissued	0	shares
CY2017Q4	galt	Undesignated Capital Stock Par Value UndesignatedCapitalStockParValue	0.01
CY2017Q4	galt	Undesignated Capital Stock Value UndesignatedCapitalStockValue	0
CY2008Q1	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2008Q1	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0251	pure
CY2008Q2	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	502000
CY2008Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	100000
CY2009Q1	galt	Class Of Warrant Or Right Issuable ClassOfWarrantOrRightIssuable	6000000	shares
CY2016Q3	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1500000
CY2010Q4	galt	Class Of Warrant Or Right Issued In Period ClassOfWarrantOrRightIssuedInPeriod	500	shares
CY2016Q4	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1008000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22697323	shares
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Type DocumentType	10-K
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.721	pure
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001133416
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P5Y
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15892000
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2017	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P6Y2M23D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
CY2017	dei	Trading Symbol TradingSymbol	GALT
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Concentration of Credit Risk.</i> Financial instruments that subject the Company to credit risk consist of cash and cash equivalents and certificates of deposit. The Company maintains cash and cash equivalents and certificates of deposit with well-capitalized financial institutions. At times, those amounts may exceed federally insured limits. The Company has no significant concentrations of credit risk.</p> </div>
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038	pure
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.39
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0205	pure
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M7D
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.88
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35521000	shares
CY2017	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"><b>Nature of Business and Basis of Presentation</b></td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> Galectin Therapeutics Inc. and subsidiaries (the “Company”) is a clinical stage biopharmaceutical company that is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. These candidates are based on the Company’s targeting of galectin proteins which are key mediators of biologic and pathologic function. These compounds also may have application for drugs to treat other diseases and chronic health conditions.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company was founded in July 2000, was incorporated in the State of Nevada in January 2001 under the name “Pro-Pharmaceuticals, Inc.,” and changed its name to “Galectin Therapeutics Inc.” on May 26, 2011. On March 23, 2012, the Company effected a one-for-six reverse stock split. All common share and per share amounts in these financial statements have been adjusted to reflect the effect of the reverse split.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company has operated at a loss since its inception and has had no revenues. The Company anticipates that losses will continue for the foreseeable future. At December 31, 2017, the Company had $3,053,000 of unrestricted cash and cash equivalents available to fund future operations. In December 2017, the Company announced a new $10 million unsecured line of credit facility with stockholder and director, Richard E. Uihlein (See Note 8). Additionally, in January 2018, the Company received $4,452,000 in proceeds from the exercise of common stock purchase warrants originally issued in November 2015. The Company believes there is sufficient cash, including availability of the line of credit, to fund currently planned operations at least through March 31, 2019. We will require more cash to fund our operations after March 31, 2019 and believe we will be able to obtain additional financing. However, there can be no assurance that we will be successful in obtaining such new financing or, if available, that such financing will be on terms favorable to us. If we are unsuccessful in raising additional capital to fund operations before March 31, 2019, we may be required to cease operations.</p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"> The Company is subject to a number of risks similar to those of clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research operations, need for regulatory approval of products, risks associated with protection of intellectual property, and competition with larger, better-capitalized companies. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations is dependent upon future events, including obtaining adequate financing to fulfill its development activities and achieving a level of revenues adequate to support the Company’s cost structure. There are no assurances that the Company will be able to obtain additional financing on favorable terms, or at all, or successfully market its products.</p> </div>
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-1.131	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.049	pure
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	498375	shares
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1142441	shares
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Use of Estimates.</i> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that may affect the reported amounts of assets, liabilities, equity, revenue, expenses and related disclosure of contingent assets and liabilities. Management’s estimates and judgments include assumptions used in stock option and warrant liability valuations, useful lives of property and equipment and intangible assets, accrued liabilities, deferred income taxes and various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates under different assumptions or conditions.</p> </div>
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P0Y11M8D
CY2017	dei	Entity Registrant Name EntityRegistrantName	GALECTIN THERAPEUTICS INC
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.03	pure
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1066000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-16247000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-16235000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1097000
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	4000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000
CY2017	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3383000
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-17467000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	696000
CY2017	us-gaap	Interest Expense InterestExpense	12000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1000
CY2017	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	33000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1232000
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3583000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1101000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	12000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4526000
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	12000
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	49000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3583000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11721000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1000
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-12309000
CY2017	us-gaap	Deferred Tax Expense From Stock Options Exercised DeferredTaxExpenseFromStockOptionsExercised	1414000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-812000
CY2017	us-gaap	Operating Expenses OperatingExpenses	16247000
CY2017	galt	Accrued Research And Development Costs And Other AccruedResearchAndDevelopmentCostsAndOther	1428000
CY2017	galt	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	200000
CY2017	galt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.017	pure
CY2017	galt	Issuance Of Warrants Value IssuanceOfWarrantsValue	696000
CY2017	galt	Supplemental Dividends On Convertible Preferred Stock SupplementalDividendsOnConvertiblePreferredStock	1232000
CY2017	galt	Common Stock Purchase Warrants Issued Related With Line Of Credit CommonStockPurchaseWarrantsIssuedRelatedWithLineOfCredit	696000
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22457466	shares
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34	pure
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.338	pure
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16409000
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037	pure
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.41
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.97
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0149	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	120187	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.97
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	29216000	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1434750	shares
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	963126	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.76
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.00	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.96	pure
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	-41000
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	3682000
CY2016	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	5458000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-21481000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-21436000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2479000
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	45000
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	416000
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22350000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-122000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0
CY2016	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	741000
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5925000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	2479000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	0
CY2016	galt	Effective Income Tax Rate Reconciliation Expiring State Non Operating Loss EffectiveIncomeTaxRateReconciliationExpiringStateNonOperatingLoss	-0.016	pure
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6156000
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	50000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5925000
CY2016	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	173000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15325000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	7000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-10484000
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2419000
CY2016	us-gaap	Operating Expenses OperatingExpenses	21481000
CY2016	galt	Accretion Of Redeemable Convertible Preferred Stock AccretionOfRedeemableConvertiblePreferredStock	132000
CY2016	galt	Accrued Research And Development Costs And Other AccruedResearchAndDevelopmentCostsAndOther	2174000
CY2016	galt	Stock And Warrants Issued During Period Value New Issues StockAndWarrantsIssuedDuringPeriodValueNewIssues	3000000
CY2016	galt	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.023	pure
CY2016	galt	Supplemental Dividends On Convertible Preferred Stock SupplementalDividendsOnConvertiblePreferredStock	742000

Files In Submission

Name	View Source	Status
0001193125-18-100592-index-headers.html	Edgar Link	pending
0001193125-18-100592-index.html	Edgar Link	pending
0001193125-18-100592.txt	Edgar Link	pending
0001193125-18-100592-xbrl.zip	Edgar Link	pending
d498563d10k.htm	Edgar Link	pending
d498563dex211.htm	Edgar Link	pending
d498563dex231.htm	Edgar Link	pending
d498563dex311.htm	Edgar Link	pending
d498563dex312.htm	Edgar Link	pending
d498563dex321.htm	Edgar Link	pending
d498563dex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
galt-20171231.xml	Edgar Link	completed
galt-20171231.xsd	Edgar Link	pending
galt-20171231_cal.xml	Edgar Link	unprocessable
galt-20171231_def.xml	Edgar Link	unprocessable
galt-20171231_lab.xml	Edgar Link	unprocessable
galt-20171231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GALT
GALECTIN THERAPEUTICS INC Stock $galt

2018 Q1 Form 10-K Financial Statement

#000119312518100592 Filed on March 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GALT GALECTIN THERAPEUTICS INC Stock $galt

2018 Q1 Form 10-K Financial Statement

#000119312518100592 Filed on March 29, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GALT
GALECTIN THERAPEUTICS INC Stock $galt